www.bioss.com.cn
400-901-9800
sales@bioss.com.cn
support@bioss.com.cn

Product Details

Product name:	**Anti-human B7-H1 / PD-L1 / CD274 (atezolizumab Biosimilar)**	**SKU:**	**BIO0063SM**
Target Name:	**B7-H1 / PD-L1 / CD274**	**Size:**	**1 mg/5 mg/20 mg**
Target Uniprot:	**Q9NZQ7**	**Concentration:**	**Lyophilized**
Clone#:	**atezolizumab**	**Isotype:**	**Human IgG1**
Reactivity:	**Human, Mouse, Cynomolgus**	**Calculated M.W.:**	**145 kDa**
Application:	**ELISA, Bioactivity: FACS, Functional assay, Research in vivo**	**Endotoxin:**	**<0.001 EU/ug**
Formulation:	**0.1M Pro, 20mM Arg, pH5.0**	**Conjugation:**	**None**
Storage:	**For long term storage, the produce should be stored at -20° C or lower.**	**Expression System:**	**CHO**
Reconstitution:	**Dissolve with sterile ddH2O**	**Purification:**	**Protein A**

Data

Purity:SDS-PAGE



Anti-B7-H1 / PD-L1 / CD274 (atezolizumab) onSDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.

Purity:SEC-HPLC



The purity of Anti-B7-H1 / PD-L1 / CD274(atezolizumab) is 100%, determined by SEC-HPLC.

Bioactivity:ELISA



Immobilized human PD-L1 His at 2 ug/mL can bind Anti-B7-H1 / PD-L1 / CD274 (atezolizumab), EC50=0.005894 ug/mL.

Bioactivity:FACS



Human PD-L1 CHO-K cells were stained with Anti-B7-H1 / PD-L1 / CD274 (atezolizumab) and negative control protein respectively, washed and then followed by PE and analyzed with FACS, EC50=1.533 nM.

400-901-9800
sales@bioss.com.cn
support@bioss.com.cn

Function:Internalization



The endocytosis ratio atezolizumab by HCC827 increased with the increase of antibody concentration, and the Internalization Rate (%) reached 60% at antibody concentration of 0.5 nM.

Research in vivo



Atezolizumab inhibited the tumor growth of MC38 on C57BL/6N mice. The result showed significant anti-tumor effects, with an tumor inhibition rate (TGI) of 85.2% at 2 mpk at D35.